|Bid||205.55 x 100|
|Ask||230.00 x 300|
|Day's range||212.77 - 215.33|
|52-week range||140.00 - 215.33|
|PE ratio (TTM)||36.61|
|Earnings date||31 Jan 2018|
|Forward dividend & yield||0.60 (0.28%)|
|1y target est||222.00|
Thermo Fisher (TMO) already derives synergies from the acquisition of FEI that largely adds capabilities to its analytical instruments portfolio.
Dublin, Jan. 18, 2018 (GLOBE NEWSWIRE) -- The "qPCR and dPCR Instrumentation - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin America. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. ...
Thermo Fisher Scientific[ticker symb=TMO] is in a potential buying range ahead of its next quarterly report, expected on Jan. 31. It's trading approximately 4% above a 201.30 buy point from a first-stage flat base. Understand that buying a stock just ahead of earnings can be risky since you typically don't have enough time to build a profit cushion before the...
How Is Accelerate Diagnostics Positioned at the Start of 2018? In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock. As a result of the offering, the cash position of the company increased to $121.3 million at the end of 3Q17 as compared with $77.8 million at the end of 3Q16.
How Is Accelerate Diagnostics Positioned at the Start of 2018? The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17. For fiscal 2017, Accelerate Diagnostics is expected to report revenues of $5 million, while peers Becton Dickinson (BDX), Bruker (BRKR), and Thermo Fisher Scientific (TMO) are expected to report revenues of $12 billion, $1.7 billion, and $20.5 billion, respectively.
Tuscon-based Accelerate Diagnostics (AXDX) is a diagnostics company focused on developing solutions and tools to provide rapid diagnostic results. While results from traditional culture-based tests usually take two to three days, Accelerate’s technology platform is built to deliver substantially faster and more accurate testing of infectious pathogens. The platform is intended to rapidly diagnose infectious pathogens.
Thermo Fisher Scientific shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.
On completion of Phenom-World purchase, Thermo Fisher (TMO) plans to integrate the business into its Analytical Instruments segment.
TMO stock reported its 52-week high of $201.20 on October 26, 2017, when the company released its 3Q17 earnings results.
On December 4, 2017, Leerink Swann reaffirmed its "outperform" rating on Thermo Fisher Scientific (TMO). It decreased its target price on TMO stock from $216.00 per share to $200.00 per share....
On December 4, 2017, Leerink Swan reiterated its "overweight" rating on TMO stock. The investment research firm has a 12-month target price of $200.00 per share on the stock.
On December 28, Becton, Dickinson and Company (BDX), or BD, closed trading on the day at $214.32 per share. Currently, BD stock's 50-day moving average stands at $221.22.
On December 4, 2017, Thermo Fisher Scientific (TMO) completed the acquisition of some assets from EPTEK Technology and related entities that have offices in mainland China and Taiwan.
On December 7, 2017, Thermo Fisher Scientific (TMO) announced that its Oncomine Dx Target Test had been proposed for coverage by the CMS (Centers for Medicare & Medicaid Services).
Thermo Fisher Scientific's (TMO) Core Informatics' Platform for Science's modules, including a LIMS (laboratory information management system), could soon be implemented at Sema4's two major laboratory ...